2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
January 22nd, 2025
Version: 1
BioISI, Faculdade de Ciencias, Universidade de Lisboa, 1749-016 Lisbon, Portugal
cancer biology
biorxiv

When neighbours play a role: a systems-level analysis of protein interactions conditioning cancer driver mutation effects

Vital, M. F.Open in Google Scholar•Miranda, J. A.Open in Google Scholar•Carrolo, M.Open in Google Scholar•Quintela, A.Open in Google Scholar•Pinto, F. R.Open in Google Scholar

Background: Cancer is driven by the accumulation of somatic mutations, including driver mutations that confer a selective advantage to cancer cells. Driver proteins operate within complex interaction networks, and their activity is conditioned by neighbour proteins. Understanding the interplay between driver mutations and the expression of their neighbour proteins can provide insights into cancer biology and potential therapeutic targets. Methods: We assessed associations between expression of neighbour proteins and driver mutation status, comparing both between and within cancer types. We further evaluated if neighbours were enriched in significant associations with multiple drivers and characterised the impact of neighbour expression on overall survival for all cancer types. Results: We found a significant correlation between the number of driver associations a neighbour gene has and the number of sign-coherent survival associations, particularly for neighbours enriched in positive associations, where high neighbour expression correlated with increased driver mutations and poorer survival. We identified 247 neighbours simultaneously enriched in positive driver and survival associations and 39 neighbours simultaneously enriched in negative driver and survival associations. Conclusions: Our study systematically identified neighbours associated with driver mutation status. Complementary evidence from survival analysis and the literature suggests that neighbours enriched in driver associations are promising drug target candidates.

Similar Papers

biorxiv
Thu May 08 2025
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 i...
Dreute, J.
•
Stengel, J.
•
Becher, J.
•
van den Borre, D. R.
...•
Schmitz, M. L.
biorxiv
Thu May 08 2025
Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62
Loss-of-function mutations in autophagy-related (ATG) genes are rare in cancer. However, we report herein that ATG5 is fully deleted in ~14% of prostate cancers (PCa), rivaling that of well-established tumor suppressor genes. ATG5 expression was downregulated at both mRNA and protein levels and was associated with poor patient survival. The DU145 PCa cell line, isolated from a brain metastasis, is...
Wible, D. J.
•
Li, W.
•
Liu, X.
•
Sebastian, M. M.
...•
Bratton, S. B.
biorxiv
Thu May 08 2025
WITHDRAWN: Oncostratifier: Stratifying Oncogene-addicted Cohorts By Drug Response
Oncogenes, when mutated or overexpressed, drive tumorigenesis and can lead to oncogene addiction, where cancer cells rely on such genes for survival and proliferation. Stratifying oncogene-addicted cohorts is essential to uncover alternative therapeutic avenues, for instance in cases of untargetable oncogenes or resistance to treatment. We propose Oncostratifier, a framework to identify drugs that...
Tepeli, Y. I.
•
Trastulla, L.
•
Goncalves, J. P.
•
Iorio, F.
biorxiv
Thu May 08 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.
DNA hypomethylating agents (HMAs) are used to treat acute myeloid leukemia (AML) and myelodysplasia patients who are unsuitable for intensive chemotherapy. However, low response rates and therapy-resistant relapse remain significant challenges. To improve outcomes, we must understand how AML cells survive HMA treatment and continue to proliferate following therapy. We combine single-cell multiomic...
Bond, D. R.
•
Burnard, S. M.
•
Uddipto, K.
•
Hunt, K. V.
...•
Lee, H. J.
biorxiv
Thu May 08 2025
Metabolic modulation of intratumoral cholesterol with gut microbiota for the treatment of colorectal cancer
Excess cholesterol is positively correlated with colorectal cancer (CRC). Current therapeutic strategies for modulating cholesterol levels in CRC are limited and often come with complications. Here, we demonstrated that microbiome shunting of intestinal cholesterol to anticancer metabolites is a safe and applicable therapeutic approach for CRC. By screening major microbial metabolic products of ch...
Wu, J.
•
Lai, Y.
•
Li, J.
•
Zhai, L.
...•
Wong, H. L. X.
biorxiv
Thu May 08 2025
Plasma Exosomes in Insulin Resistant Obesity Exacerbate Progression of Triple Negative Breast Cancer
Breast cancer, the most common cancer among women worldwide, continues to pose significant public health challenges. Among the subtypes of breast cancer, triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat due to the absence of receptors for estrogen, progesterone, or human epidermal growth factor receptor 2, rendering TNBC refractory to conventional targeted the...
Llevenes, P.
•
Chen, A.
•
Lawton, M. L.
•
Rondon-Ortiz, A. N.
...•
Denis, G. V.
biorxiv
Wed May 07 2025
Miro1 knockout inhibits mouse breast cancer tumorigenesis
Miro1 is a mitochondrial outer membrane protein that regulates mitochondrial and peroxisome trafficking, endoplasmic reticulum (ER) association, and mitophagy. Prior studies suggest a role for Miro1 in cell migration and proliferation in both normal and tumor cells. High Miro1 expression is associated with poor overall survival in breast cancer patients. To investigate the role of Miro1 in breast ...
Termos, R.
•
Muskat, A.
•
Shannon, N.
•
McCoy, M.
...•
Cunniff, B.
biorxiv
Wed May 07 2025
IRE1α and IRE1β Protect Intestinal Epithelium and Suppress Colorectal Tumorigenesis through Distinct Mechanisms
Intestinal epithelial cells (IECs) uniquely express two IRE1 paralogues, IRE1 and IRE1{beta}, whose roles in intestinal physiology are incompletely understood. We examined the individual and cooperative functions of IRE1 and IRE1{beta} in IECs using mice using intestine-specific deletion of Ire1 or germline Ire1{beta} deletion, and subsequently with double deleted Ire1, Ire1{beta} mice. At baselin...
Deng, R.
•
Wang, M.
•
Promlek, T.
•
Druelle-Cedano, C.
...•
Kaufman, R. J.
biorxiv
Wed May 07 2025
Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth
Diffuse infiltrating gliomas are aggressive tumors of the central nervous system driven by intra-tumoral heterogeneity and aberrant normal-tumor cell-cell interactions. Grade specific and locoregional metabolic dependencies driving aberrant cell-states linked to treatment resistance, seizures and infiltration of gliomas remain elusive. Here, we applied spatial transcriptomics (stRNAseq), imaging m...
Ma, Y.
•
Ayadhury, S.
•
Singh, S.
•
Vashishath, Y.
...•
Ene, C. I.
biorxiv
Wed May 07 2025
Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal...
Dutta, A.
•
Chowdhury, N.
•
Selvarajan, A. V.
•
Banerjee, P.
...•
GuhaSarkar, D.